Article

TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS

2025-11-19

Abstract excerpt

Occasional complete responses to immune checkpoint inhibitor therapies suggest that acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are immune-sensitive when appropriately targeted. Here, we analyzed AML/MDS patients treated with anti-TIM3 sabatolimab and decitabine in a phase Ib clinical trial ( NCT03066648 ) using single-cell RNA and T cell receptor (TCR) sequencing and functional co-culture ass...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 4f35e4b7-593f-5c02-9138-658a5d69e83a
DOI: 10.1101/2025.11.14.25339889

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDSDOI 10.1101/2025.11.14.25339889Read

Ex vivo characterization of acute myeloid leukemia patients undergoing hypomethylating agents and venetoclax regimen reveals a venetoclax-specific effect on non-suppressive regulatory T cells and bona fide PD-1+TIM3+ exhausted CD8+ T cellsSemantic proximity Read

Signatures of CD8+ T cell dysfunction in AML patients and their reversibility with response to chemotherapySemantic proximity Read

Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-CellsSemantic proximity Read

Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agentsSemantic proximity Read

Azacytidine restores T cell function in AML by modulating DNA methylationSemantic proximity Read

Single-cell Characterization of Acute Myeloid Leukemia and its Microenvironment Following PD-1 Blockade Based TherapySemantic proximity Read

Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.Semantic proximity Read

TIM-3 Expression Level on AML Blasts Correlates With Presence of Core Binding Factor Translocations Rather Than Clinical OutcomesSemantic proximity Read

Immunological effects of hypomethylating agents.Semantic proximity Read

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.Semantic proximity Read

Pan-cancer analysis to provide a reliable basis for the clinical use of TIM-3 immunosuppressantsSemantic proximity Read

CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.Semantic proximity Read